Natpara (parathyroid hormone)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
June 2016
WARNINGS AND PRECAUTIONS
Hypercalcemia
In the pivotal trial, 3 patients randomized to NATPARA required administration...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts